• Company Type For Profit
  • Contact Email contact@nosopharm.com
  • Phone Number +330466265321

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections.

Nosopharm has set up an innovative anti-infective drug discovery platform based on the

medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Lists Featuring This Company

European Union (EU) Companies With Less Than $50M in Revenue (Top 10K)
9,842 Number of Organizations • $246.5B Total Funding Amount • 42,980 Number of Investors
Europe, Middle East, and Africa (EMEA) Product Research Companies
2,167 Number of Organizations • $1.4B Total Funding Amount • 562 Number of Investors
Pharmaceutical Companies With Less Than $50M in Revenue (Top 10K)
9,670 Number of Organizations • $186.2B Total Funding Amount • 11,871 Number of Investors
Pharmaceutical Companies With Fewer Than 50 Employees (Top 10K)
9,652 Number of Organizations • $76.5B Total Funding Amount • 10,102 Number of Investors

Frequently Asked Questions

Where is Nosopharm's headquarters? Nosopharm is located in Nîmes, Languedoc-Roussillon, France.Who invested in Nosopharm? Nosopharm has 4 investors including Bpifrance and Auriga Partners.How much funding has Nosopharm raised to date? Nosopharm has raised .When was the last funding round for Nosopharm? Nosopharm closed its last funding round on Feb 12, 2018 from a Debt Financing round.Who are Nosopharm's competitors? Alternatives and possible competitors to Nosopharm may include Aura BiosciencesImvax, and 1859.